An editorial notes that similar to second-generation antipsychotics, lumateperone has antagonist effects at the D2 and 5-HT2A receptors, and it remains possible that lumateperone is just another “me-too” second-generation antipsychotic. Nevertheless, several of its pharmacologic properties bolster the potential for a novel mechanism. It adds that it remains to be seen whether lumateperone has equivalent or greater efficacy to the most effective drugs, such as olanzapine or risperidone, much less clozapine, or whether it is a more metabolically friendly but modestly efficacious antipsychotic. Either way, lumateperone appears useful, but further research is needed to determine its ultimate comparative ranking.